申请人:——
公开号:US20040023960A1
公开(公告)日:2004-02-05
This invention is concerned with mammalian metabolites of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist that is useful in the prevention and treatment of certain disorders, including emesis and psychiatric disorders such as depression and anxiety.
这项发明涉及化合物2-(R)-(1-(R)-(3,5-双三氟甲基苯基)乙氧基)-3-(S)-(4-氟苯基)-4-(3-(5-氧代-1H,4H-1,2,4-三唑基)甲基吗啡啶的哺乳动物代谢产物。该化合物是一种缓释激肽受体拮抗剂,可用于预防和治疗某些疾病,包括呕吐和精神障碍,如抑郁症和焦虑症。